175 results on '"Morelli M.C."'
Search Results
2. The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study
3. Nationwide survey of liver transplantation for Primary Sclerosing Cholangitis in Italy
4. Risk Factors for Infection With Carbapenem-Resistant Klebsiella pneumoniae
5. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C
6. SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study
7. Can the Dropout Risk of Candidates with Hepatocellular Carcinoma Predict Survival after Liver Transplantation?
8. Harm and Benefits of Primary Liver Resection and Salvage Transplantation for Hepatocellular Carcinoma
9. Eating habits in patients affected by metabolic syndrome and liver disease (hepatitis, cirrhosis and liver transplant)
10. Liver transplant recipients with Covid-19: results from an Italian multicenter cohort
11. Liver transplant candidates and SARS-CoV-2 infection: Results from an Italian multicenter cohort
12. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
13. CASE REPORT: Severe and Relapsing Upper Gastrointestinal Bleeding in a Patient with Glanzmann's Thrombasthenia
14. Recent trends and intention-to-treat survival of liver transplantation for nonalcoholic steatohepatitis: an Italian liver transplant registry study
15. Combined effect of recipient age and graft fibrosis on liver transplantation outcomes: Tailoring the best donor/recipient match in the extended criteria age
16. Budesonide Down-Regulates Eosinophil Locomotion But Has No Effects on ECP Release or on [H.sub.2]O.sub.2 Production
17. Social and labor market reintegration of the transplanted patient
18. The effects of source and concentration of dietary fiber, starch, and fatty acids on the daily patterns of feed intake, rumination, and rumen pH in dairy cows
19. DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods
20. DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods
21. Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice
22. Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study
23. LP51 : Treatment of severe HCV recurrence after liver transplantation with sofosbuvir based regimen: Results of the aisf-sofolt Italian compassionate use program
24. ECHO-COLOUR-DOPPLER CHARACTERIZATION OF CIRRHOTIC PATIENTS RESPONDERS AND NON-RESPONDERS TO NADOLOL AS PRIMARY PROPHYLAXIS
25. P885 RECIPIENT AND DONOR GENDER MATCH PREDICTS THE OUTCOME OF ANTIVIRAL THERAPY FOR RECURRENT HEPATITIS C
26. The impact of IL-28B polymorphism and diabetes on SVR after antiviral therapy (AT) for post-liver transplant (LT) HCV recurrence
27. Recipient and donor gender match predicts the outcome of antiviral therapy for recurrent hepatitis C
28. P.18.2 LONG-TERM MAINTENANCE OF SVR IN DIFFICULT-TO-TREAT HCV GENOTYPES IN LIVER TRANSPLANT RECIPIENTS WITH HCV RECURRENCE
29. 563 ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FORM THE AISF-RECOLT-C GROUP
30. P.1.54: TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN “AISF RECOLT-C” STUDY
31. 551 DONOR-RELATED CHARACTERISTICS AS PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION
32. P.1.3: ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT LIVER TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
33. P.1.2: THE PERSISTENCE OF HCV REPLICATION IS ASSOCIATED WITH AN INCREASED MORTALITY RATE IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
34. PC.1.4: THE BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
35. 31 CD4+CD25HIFOXP3+ T-REGS AND LIVER TRANSPLANTATION FOR END-STAGE HCV-RELATED LIVER DISEASE: A ROLE IN HCV RECURRENCE?
36. 427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME
37. 512 INVERSION OF GAMMA-DELTA T-CELL SUBSET RATIO BEFORE AND AFTER LIVER TRANSPLANTATION FOR END-STAGE HCV-RELATED LIVER DISEASE
38. 464 TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN ITALIAN MULTICENTRIC EXPERIENCE
39. P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP
40. T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group
41. T-43 Treatment of the “uncommon” HCV genotype 4 infection recurrence after liver transplantation. Data from AISF RECOLT-C group
42. F-31 The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
43. T-23 Poor adherence to pegylated interferon and ribavirin is a major concern in the treatment of hepatitis C after liver transplantation: Evidence from the AISF RECOLT-C study group
44. F-10 Acute and chronic rejection during interferon therapy in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
45. F-19 CD4+CD25hiFoxp3+ T-regs and liver transplantation for and-stage HCV-related liver disease: A role in HCV recurrence?
46. OC-24 The best matching for HCV genotype 1 liver transplant recipients is predicted by HCV1-STAR. A study from “AISF RECOLT-C” database
47. F.N.35 IMMUNOLOGY IN LIVER TRANSPLANTATION FOR END-STAGE HCV-RELATED LIVER DISEASE: A PRELIMINARY STUDY ON T REGULATORY CELL KINETICS
48. T.N.49 FIBROSIS PROGRESSION IN NON RESPONDERS TO ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION (LT)
49. Monitoring Cytomegalovirus T-Cell Immunity in Small Bowel/Multivisceral Transplant Recipients
50. 466 NATREMIA AND CHILD-TURCOTTE-PUGH (CTP) SCORE MAY IMPROVE THE SELECTION OF CANDIDATES FOR LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.